drug · antibody
daratumumab
pre_registrationupdated 3mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 8- drugdaratumumab + Gene Therapy63 co-mentions · 18 sources
- drugDARZALEX FASPRO60 co-mentions · 15 sources
- tagApproval60 co-mentions · 15 sources
- drug(daratumumab + hyaluronidase (human recombinant))31 co-mentions · 16 sources
- companyJanssen Biotech Inc30 co-mentions · 15 sources
- tagOncology3 co-mentions · 2 sources
- tagImmunology2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm and 37 investigational indications.
targets
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
all catalysts(0)
nothing on the calendar yet
Trials studying daratumumab
- phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
- phase3A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
- phase1A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
- phase3A Study of Daratumumab
- phase3A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- phase2Pan Tumor Rollover Study
- phase3A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- phase2A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
News(7)
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.fiercebiotech · 15d ago
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.biopharma_dive · 27d ago
- Medicare drug price rule may target under-the-skin Keytruda and OpdivoFor 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.biopharma_dive · 1mo ago
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 1mo ago
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BThe buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.biopharma_dive · 2mo ago
- 2026 Orphan Drugs Report: A safe(r) passage amid stormy waters?Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipelinebiopharma_dive · 2mo ago
- FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotechThrough two pioneering studies, Amgen and AstraZeneca will share study data with FDA scientists as it’s accrued. Elsewhere, Lilly inked a gene editing deal and Pfizer reported success for a multipl…biopharma_dive · 3mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that